We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Zohydro ER Rejected by FDA Panel Due to Abuse Potential
Zohydro ER Rejected by FDA Panel Due to Abuse Potential
December 14, 2012
An FDA advisory panel voted down Zogenix’s Zohydro ER due to concerns on its potential for abuse and addiction.